SEHK:6990Biotechs
A Look at Sichuan Kelun-Biotech (SEHK:6990) Valuation After New Sacituzumab Tirumotecan Clinical Data Revealed
Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) drew attention at the 2025 Chinese Congress on Holistic Integrative Oncology with presentations on sacituzumab tirumotecan, its TROP2 ADC therapy. The company detailed encouraging safety data and regulatory momentum across several cancer types.
See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical.
Sichuan Kelun-Biotech Biopharmaceutical’s breakthrough cancer drug developments have grabbed headlines, but what’s really fueled...